Press "Enter" to skip to content

AstraZeneca’s Lynparza gets EU nod as first-line ovarian cancer maintenance treatment

BRCA genes are responsible for producing proteins which repair damaged DNA, and if the genes are mutated, they can cause cancer growth.

Original source: https://health.economictimes.indiatimes.com/news/pharma/astrazenecas-lynparza-gets-eu-nod-as-first-line-ovarian-cancer-maintenance-treatment/69843171?utm_source=RSS&utm_medium=ETRSS

Also Read:   Roche Pharma India expands partnership with Cipla for key oncology medicines